Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Durvalumab + Poly ICLC + PVX-410|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 86||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|PVX-410||PVX-410 is a multipeptide vaccine that may stimulate anti-tumor immune response (PMID: 30128502).|
|Poly ICLC||Hiltonol||Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02826434||Phase I||Durvalumab + Poly ICLC + PVX-410||Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer||Active, not recruiting||USA||0|